V3 here soon-try beta now


Gene Search (GeneCards Home)	\|	GeneCards Guide	\|	User Feedback	\|	Terms of Use	\|	Notice about third-party sites

TP53 Gene

protein-coding GIFtS: 82

GC17M007512

tumor protein p53
Symbol approved by the HUGO Gene Nomenclature Committee (HGNC) database

(According to ¹HGNC, ²Entrez Gene,
³UniProtKB/Swiss-Prot, ⁴UniProtKB/TrEMBL, ⁵OMIM, ⁶GeneLoc , and/or ⁷Ensembl, ⁸miRBase)
About This Section

Aliases
FLJ92943 ^²
LFS1 ^¹, ², ⁵
P53 ^³, ⁵
TRP53 ^²
p53 ^¹, ²

Descriptions
Antigen NY-CO-13 ^³
Phosphoprotein p53 ^², ³
Tumor suppressor p53 ^³
p53 antigen ^²
p53 transformation suppressor ^²
p53 tumor suppressor ^²
transformation-related protein 53 ^²
tumor protein p53 ^²

External Ids
HGNC: 11998¹
Entrez Gene: 7157²
UniProtKB: P04637³
Ensembl: ENSG00000141510⁷

Search outside databases for aliases for TP53 gene

Previous GC identifers: GC17P008026 GC17M008311 GC17M007514 GC17M007772

(According to Entrez Gene, Wikipedia's Gene Wiki,
UniProtKB/Swiss-Prot, and/or UniProtKB/TrEMBL)
About This Section

EntrezGene summary for TP53:

This gene encodes tumor protein p53, which responds to diverse cellular stresses to regulate target

genes that induce cell cycle arrest, apoptosis, senescence, DNA repair, or changes in metabolism.

p53 protein is expressed at low level in normal cells and at a high level in a variety of

transformed cell lines, where it's believed to contribute to transformation and malignancy.

p53 is a DNA-binding protein containing transcription activation, DNA-binding, and oligomerization

domains. It is postulated to bind to a p53-binding site and activate expression of downstream

genes that inhibit growth and/or invasion, and thus function as a tumor suppressor. Mutants of p53

that frequently occur in a number of different human cancers fail to bind the consensus DNA

binding site, and hence cause the loss of tumor suppressor activity. Alterations of this gene

occur not only as somatic mutations in human malignancies, but also as germline mutations in some

cancer-prone families with Li-Fraumeni syndrome. Multiple p53 variants due to alternative

promoters and multiple alternative splicing have been found. These variants encode distinct

isoforms, which can regulate p53 transcriptional activity. [provided by RefSeq]

UniProtKB/Swiss-Prot: P53_HUMAN, P04637

Function: Acts as a tumor suppressor in many tumor types; induces growth arrest or apoptosis

depending on the physiological circumstances and cell type. Involved in cell cycle regulation as a

trans-activator that acts to negatively regulate cell division by controlling a set of genes

required for this process. One of the activated genes is an inhibitor of cyclin-dependent kinases.

Apoptosis induction seems to be mediated either by stimulation of BAX and FAS antigen expression,

or by repression of Bcl-2 expression. Implicated in Notch signaling cross-over

Gene Wiki entry for TP53 (P53)

(According to GeneLoc and/or HGNC, and/or
Entrez Gene (NCBI build 36),
and/or miRBase,
Genomic Views according to UCSC and Ensembl, Transcription factor binding sites according to SABiosciences)
About This Section

Genomic View:

UCSC Golden Path with GeneCards custom track

Transcription factor binding sites upstream to the TP53 gene

Entrez Gene cytogenetic band: 17p13.1 Ensembl cytogenetic band: 17p13.1 HGNC cytogenetic band: 17p13.1

TP53 Gene in genomic location: bands according to Ensembl, locations according to (and/or Entrez Gene and/or Ensembl if different)

GeneLoc gene densities for chromosome 17 GeneLoc Exon Structure

GeneLoc location for GC17M007512: (about GC identifiers)

Start:	7,512,445 bp from pter
End:	7,531,642 bp from pter
Size:	19,198 bases
Orientation:	minus strand

RefSeq DNA sequence:

NC_000017.9 NT_010718.15

(According to ¹UniProtKB, and/or Ensembl, Phosphorylation sites according to ²Phosphosite, RefSeq according to NCBI, PDB rendering according to OCA and/or Proteopedia, Recombinant Proteins from Invitrogen, Millipore, Sigma-Aldrich, R&D Systems, Enzo Life Sciences, Abnova, OriGene and/or, Abcam,
Biochemical Assays by Invitrogen, Millipore, R&D Systems, Cell Signaling Technology, and/or Enzo Life Sciences, Ontologies according to Gene Ontology Consortium 01 Apr 2009 and Entrez Gene, Antibodies by Invitrogen, Millipore, Sigma-Aldrich, R&D Systems, Cell Signaling Technology, Abcam, Abnova, and/or Novus Biologicals)
About This Section

UniProtKB/Swiss-Prot: P53_HUMAN, P04637 (See protein sequence)

Recommended Name: Cellular tumor antigen p53

Size: 393 amino acids; 43712 Da

Cofactor: Binds 1 zinc ion per subunit

Subunit: Interacts with AXIN1. Probably part of a complex consisting of TP53, HIPK2 and AXIN1 (By

similarity). Binds DNA as a homotetramer. Interacts with histone acetyltransferases EP300 and

methyltransferases HRMT1L2 and CARM1, and recruits them to promoters. In vitro, the interaction of

TP53 with cancer-associated/HPV (E6) viral proteins leads to ubiquitination and degradation of

TP53 giving a possible model for cell growth regulation. This complex formation requires an

additional factor, E6-AP, which stably associates with TP53 in the presence of E6. Interacts (via

C-terminus) with TAF1; when TAF1 is part of the TFIID complex. Interacts with ING4; this

interaction may be indirect. Found in a complex with CABLES1 and TP73. Interacts with HIPK1,

HIPK2, and P53DINP1. Interacts with WWOX. May interact with HCV core protein. Interacts with USP7

and SYVN1. Interacts with HSP90AB1. Interacts with CHD8; leading to recruit histone H1 and prevent

transactivation activity (By similarity). Interacts with ARMC10, BANP, CDKN2AIP and E4F1.

Interacts with YWHAZ; the interaction enhances P53 transcriptional activity. Phosphorylation of

YWHAZ on 'Ser-58' inhibits this interaction. Interacts (via DNA-binding domain) with MAML1 (via

N-terminus)

Subcellular location: Cytoplasm. Nucleus. Endoplasmic reticulum. Note=Interaction with BANP

promotes nuclear localization

PDB structures from and Proteopedia :

1A1U (3D)

1AIE (3D)

1C26 (3D)

1DT7 (3D)

1GZH (3D)

1H26 (3D)

1HS5 (3D)

1JSP (3D)

1KZY (3D)

1MA3 (3D)

1OLG (3D)

1OLH (3D)

1PES (3D)

1PET (3D)

1SAE (3D)

1SAF (3D)

1SAH (3D)

1SAJ (3D)

1SAK (3D)

1SAL (3D)

1TSR (3D)

1TUP (3D)

1UOL (3D)

1XQH (3D)

1YC5 (3D)

1YCQ (3D)

1YCR (3D)

1YCS (3D)

2AC0 (3D)

2ADY (3D)

2AHI (3D)

2ATA (3D)

2B3G (3D)

2BIM (3D)

2BIN (3D)

2BIO (3D)

2BIP (3D)

2BIQ (3D)

2F1X (3D)

2FEJ (3D)

2FOJ (3D)

2FOO (3D)

2GS0 (3D)

2H1L (3D)

2H2D (3D)

2H2F (3D)

2H4F (3D)

2H4H (3D)

2H4J (3D)

2H59 (3D)

2J0Z (3D)

2J10 (3D)

2J11 (3D)

2J1W (3D)

2J1X (3D)

2J1Y (3D)

2J1Z (3D)

2J20 (3D)

2J21 (3D)

2K8F (3D)

2OCJ (3D)

2PCX (3D)

2QVQ (3D)

2QXA (3D)

2QXB (3D)

2QXC (3D)

2VUK (3D)

2Z5S (3D)

2Z5T (3D)

3D05 (3D)

3D06 (3D)

3D07 (3D)

3D08 (3D)

3D09 (3D)

3D0A (3D)

3DAB (3D)

3DAC (3D)

3SAK (3D)

Secondary accessions: Q15086 Q15087 Q15088 Q16535 Q16807 Q16808 Q16809 Q16810 Q16811 Q16848 Q86UG1

Q8J016 Q99659 Q9BTM4 Q9HAQ8 Q9NP68 Q9NPJ2 Q9NZD0 Q9UBI2 Q9UQ61

Alternative splicing: 2 isoforms: P04637-1 P04637-2

Post-translational modifications:

Acetylated. Acetylation of Lys-382 by CREBBP enhances transcriptional activity. Deacetylation of

Lys-382 by SIRT1 impairs its ability to induce proapoptotic program and modulate cell senescence¹

Phosphorylation on Ser residues mediates transcriptional activation. Phosphorylated by HIPK1 (By

similarity). Phosphorylation at Ser-9 by HIPK4 increases repression activity on BIRC5 promoter.

Phosphorylated on Thr-18 by VRK1, which may prevent the interaction with MDM2. Phosphorylated on

Thr-55 by TAF1, which promotes MDM2-mediated degradation. Phosphorylated on Ser-46 by HIPK2 upon

UV irradiation. Phosphorylation on Ser-46 is required for acetylation by CREBBP. Phosphorylated on

Ser-392 following UV but not gamma irradiation. Phosphorylated upon DNA damage, probably by ATM or

ATR. Phosphorylated on Ser-15 upon ultraviolet irradiation; which is enhanced by interaction with

BANP¹

Dephosphorylated by PP2A. SV40 small T antigen inhibits the dephosphorylation by the AC form of

PP2A¹

May be O-glycosylated in the C-terminal basic region. Studied in EB-1 cell line¹

Ubiquitinated by SYVN1, which leads to proteasomal degradation¹

Monomethylated at Lys-372 by SETD7, leading to stabilize it and increase transcriptional

activation. Monomethylated at Lys-370 by SMYD2, leading to decrease DNA-binding activity and

subsequent transcriptional regulation activity. Lys-372 monomethylation prevents the interaction

with SMYD2 and subsequenct monomethylation at Lys-370¹

Sumoylated by SUMO1¹

Demethylation of di-methylated Lys-370 by KDM1/LSD1 prevents interaction with TP53BP1 and represses

TP53-mediated transcriptional activation¹

View phosphorylation sites using PhosphoSite²

REFSEQ proteins (7 alternative transcripts):

NP_000537.3 NP_001119584.1 NP_001119585.1 NP_001119586.1 NP_001119587.1 NP_001119588.1 NP_001119589.1

ENSEMBL proteins:

ENSP00000379735 ENSP00000352610 ENSP00000269305

Human Recombinant Proteins

	Browse Drug Discovery Central at Invitrogen for human recombinant proteins
	Millipore Purified and/or Recombinant TP53 Protein
	Sigma-Aldrich CompoZr ZFN for TP53
	Browse R&D Systems for human recombinant proteins
	Enzo Life Sciences proteins for TP53
	Recombinant Proteins from Abcam (p53 gamma, p53, p53 beta, Mutant p53)
	Human Recombinant Proteins from Abnova (TP53)

OriGene Purified Recombinant Human Protein: TP53

5/11 Gene Ontology (GO) cellular component terms (links to tree view) (see all 11 ):

GO ID	Qualified GO term	Evidence	PubMed IDs
GO:0005626	insoluble fraction	IDA	12915590
GO:0005634	nucleus	IDA	7720704 16507995
GO:0005654	nucleoplasm	IDA	11080164 12915590
GO:0005657	replication fork	IEA	--
GO:0005730	nucleolus	IDA	12080348

About this table

Antibodies for TP53:

	Invitrogen Antibodies for TP53
	Millipore Mono- and Polyclonal Antibodies for the study of TP53
	Sigma-Aldrich Antibody Arrays and Antibodies for TP53
	R&D Systems Antibodies for TP53 (p53)
	Cell Signaling Technology (CST) Antibodies for TP53 (p53)
	Antibodies from Abcam (p53 gamma, p53, p53 beta, Mutant p53), each with their Abpromise^SM
	Monoclonal and Polyclonal Antibodies from Abnova (TP53)
	Novus Biologicals Antibodies for TP53

Assays for TP53:

	Invitrogen Assays for TP53
	Millipore Kits and Assays for the Analysis of TP53
	R&D Systems ELISAs for TP53 (p53) (see all)
	Cell Signaling Technology (CST) Sandwich ELISA Kits for TP53 (p53)
	Browse biochemical assays available from Enzo Life Sciences

(According to InterPro, ProtoNet, UniProtKB, and/or BLOCKS, Sets of similar genes according to GeneDecks)
About This Section

Graphical View of Domain Structure for InterPro Entry P04637

ProtoNet protein and cluster: P04637

1 Blocks protein family: IPB010991 p53

UniProtKB/Swiss-Prot: P53_HUMAN, P04637

Domain: The nuclear export signal acts as a transcriptional repression domain

Similarity: Belongs to the p53 family

(According to MGI Jun 06 2009, UniProtKB, IUBMB,and/or Genatlas,
shRNA from OriGene, Sigma-Aldrich, RNAi from Sigma-Aldrich,
RNAi Products, Clones, and Q-PCR Products from Invitrogen, Millipore, OriGene, and/or Abnova, siRNAs from Applied Biosystems, SYBR primers from OriGene, Cell-based Assays from Millipore, Ontologies according to Gene Ontology Consortium 01 Apr 2009 via Entrez Gene.)
About This Section

Inhib. RNA:		Invitrogen RNAi Products for gene knock-down (TP53)
		Millipore RNAi Products for the Analysis of TP53 Gene knock-down
		Abnova Chimera RNAi Products for Gene knock-down (TP53)

OriGene 29mer shRNA kit in GFP-retroviral vectors (see all 7): NM_001126112

Applied Biosystems Silencer® siRNAs for TP53

Sigma-Aldrich siRNA for TP53

Sigma-Aldrich shRNA Panels and shRNA for TP53

Explore Sigma-Aldrich super-pooled esiRNAs

Clones:		Invitrogen Clones for TP53
		Browse Clones for the Expression of Recombinant Proteins Available from Millipore

OriGene GFP tagged cDNA clones in CMV expression vector (see all 7): NM_000546
Myc/DDK tagged cDNA clones in CMV expression vector (see all 7): NM_000546
untagged cDNA clones in CMV expression vector (see all 7): NM_000546

Primers:

Browse Quantitative PCR Central at Invitrogen for Q-PCR LUX™ Primers

OriGene genome-wide validated SYBR primer pairs: NM_000546

UniProtKB/Swiss-Prot: P53_HUMAN, P04637

Function: Acts as a tumor suppressor in many tumor types; induces growth arrest or apoptosis

depending on the physiological circumstances and cell type. Involved in cell cycle regulation as a

trans-activator that acts to negatively regulate cell division by controlling a set of genes

required for this process. One of the activated genes is an inhibitor of cyclin-dependent kinases.

Apoptosis induction seems to be mediated either by stimulation of BAX and FAS antigen expression,

or by repression of Bcl-2 expression. Implicated in Notch signaling cross-over

Genatlas biochemistry entry for TP53:

tumor suppressor protein p53 required for G1 growth arrest by WAF1 (CDKN1A),following DNA damage or

induction of apoptosis,also regulating a G2 checkpoint through cyclin B1,transcriptional activator

through acetylation of transactivation site by CREBBP binding MDM2 resulting in transcriptional

silencing and ubiquitin/proteasome dependent degradation of p53,activated by conjugation to UBL1

(SUMO1),putative up-regulated c-MYC target gene,putative teratologic suppressor gene and modulator

of TFIIH (GTF2H),associated in nucleotide excision repair,activated by ATM in association with

14.3.3 proteins (YWHA*),tumor suppressor gene (see TSG17A),mutated in cancers such as pancreas and

endometrial carcinomas,in Barrett's adenocarcinoma (and esophageal squamous cell carcinoma),in

hepatocellular carcinoma with poor prognosis

15/29 MGI mutant phenotypes (inferred from 44 alleles) (MGI details for Trp53) (see all 29 ):

	adipose tissue	behavior/neurological	cellular	craniofacial
digestive/alimentary	embryogenesis	endocrine/exocrine gland	growth/size	hearing/vestibular/ear
hematopoietic system	homeostasis/metabolism	immune system	lethality-postnatal	lethality-prenatal/perinatal

5/12 Gene Ontology (GO) molecular function terms (links to tree view) (see all 12 ):

GO ID	Qualified GO term	Evidence	PubMed IDs
GO:0000739	DNA strand annealing activity	IDA	8183576
GO:0003682	chromatin binding	IDA	17599062
GO:0003700	transcription factor activity	IDA	7587074
GO:0004518	nuclease activity	TAS	11002423
GO:0005507	copper ion binding	IDA	7824276

About this table

(Pathways according to Invitrogen (maps by GeneGo), Millipore, Cell Signaling Technology, Sigma-Aldrich, KEGG and/or UniProtKB,
Sets of similar genes according to GeneDecks, Proteins Network according to SABiosciences, Interactions according to ¹UniProtKB, ²MINT, and/or ³STRING, with links to IntAct and Ensembl, Ontologies according to Gene Ontology Consortium 01 Apr 2009 via Entrez Gene.)
About This Section

5/31 Sigma-Aldrich "Your Favorite Gene" Pathways for TP53 (Your Favorite Gene powered by Ingenuity) (see all 31 )

Prostate Cancer Signaling
Role of CHK Proteins in Cell Cycle Checkpoint Control
Molecular Mechanisms of Cancer
Chronic Myeloid Leukemia Signaling
Basal Cell Carcinoma Signaling

GeneDecks TP53 for the pathways selected above

About GeneDecksing

Gene Network Central^TM Interacting Genes and Proteins Network for TP53

5/824 Interacting proteins for TP53 (ENSP00000269305³ P04637^{1, 2}) via UniProtKB, MINT, and/or STRING (see all 824 )

Interactant		Interaction Details
GeneCard	External ID(s)	Interaction Details
UBC	P62988¹^,²	STRING (score=.999) EBI-366083, EBI-413034 MINT-4051326 MINT-4304004 MINT-4054804 MINT-4304143 MINT-6801380 MINT-6615153 MINT-6541035 MINT-6799774 MINT-7013815 MINT-4052207 MINT-5114741
- - (xeno)	Q9PST7¹	EBI-366083, EBI-617698 MINT-69740 MINT-6628483 MINT-6733190 MINT-69730 MINT-73318 MINT-6628495 MINT-6628706 MINT-6733198 MINT-73205 MINT-73319 MINT-6627917 MINT-6628699 MINT-5162111 MINT-6628692 EBI-366083, EBI-1782562
RPS27AP11	P62988¹^,²	EBI-366083, EBI-413034 MINT-4051326 MINT-4304004 MINT-4054804 MINT-4304143 MINT-6801380 MINT-6615153 MINT-6541035 MINT-6799774 MINT-7013815 MINT-4052207 MINT-5114741
RPS27AP12	P62988¹^,²	EBI-366083, EBI-413034 MINT-4051326 MINT-4304004 MINT-4054804 MINT-4304143 MINT-6801380 MINT-6615153 MINT-6541035 MINT-6799774 MINT-7013815 MINT-4052207 MINT-5114741
RPS27AP16	P62988¹^,²	EBI-366083, EBI-413034 MINT-4051326 MINT-4304004 MINT-4054804 MINT-4304143 MINT-6801380 MINT-6615153 MINT-6541035 MINT-6799774 MINT-7013815 MINT-4052207 MINT-5114741
UBA52	P62988¹^,²	EBI-366083, EBI-413034 MINT-4051326 MINT-4304004 MINT-4054804 MINT-4304143 MINT-6801380 MINT-6615153 MINT-6541035 MINT-6799774 MINT-7013815 MINT-4052207 MINT-5114741
UBB	P62988¹^,²	EBI-366083, EBI-413034 MINT-4051326 MINT-4304004 MINT-4054804 MINT-4304143 MINT-6801380 MINT-6615153 MINT-6541035 MINT-6799774 MINT-7013815 MINT-4052207 MINT-5114741

About this table

5/48 Gene Ontology (GO) biological process terms (links to tree view) (see all 48 ):

GO ID	Qualified GO term	Evidence	PubMed IDs
GO:0000060	protein import into nucleus, translocation	IEA	--
GO:0000122	negative regulation of transcription from RNA polymerase II promoter	IEA	--
GO:0001701	in utero embryonic development	IEA	--
GO:0001836	release of cytochrome c from mitochondria	IEA	--
GO:0002309	T cell proliferation during immune response	IEA	--

About this table

(Chemical Compounds according to UniProtKB, Enzo Life Sciences, Sigma-Aldrich, Tocris Bioscience, and/or Novoseek and Drugs according to Enzo Life Sciences and/or PharmGKB)
About This Section

Browse drugs & compounds from Enzo Life Sciences

Browse Small Molecules at Sigma-Aldrich

Compounds for TP53 available from Tocris Bioscience

Compound	Action	CAS number
CP 31398 dihydrochloride	p53-stabilizing agent	[259199-65-0]
RETRA hydrochloride	Antitumor agent; suppresses mutant p53-bearing cancer cells	[1036069-26-7]
Pifithrin-alpha hydrobromide	p53 inhibitor. Also aryl hydrocarbon receptor agonist	[63208-82-2]
MIRA-1	Restores mutant p53 activity; proapoptotic	[72835-26-8]
RITA	p53-MDM2 interaction inhibitor; antitumor	[213261-59-7]

About this table

10/18 Novoseek chemical compound relationships for TP53 gene (see all 18 )

Compound	Score	Articles	PubMed IDs for Articles with Shared Sentences (# sentences)
hpvs	70.81	69	11002226 (2), 8726818 (2), 9714244 (1), 10029413 (1) (see all 48)
noxa	70.34	71	17216584 (4), 17653088 (3), 15598651 (3), 15878356 (2) (see all 41)
progesterone	68.44	658	12416559 (6), 14595509 (5), 9635673 (5), 9744308 (5) (see all 99)
aflatoxin b1	63.74	200	16280384 (6), 8921985 (5), 1310637 (5), 10446974 (5) (see all 88)
advexin	57.44	9	19086841 (2), 16856803 (2), 12749760 (2), 17483435 (1)
crcs	56.64	37	10533474 (4), 16084947 (3), 11037343 (2), 19147861 (2) (see all 18)
bpde	55.33	104	7586197 (6), 17630511 (6), 10786695 (5), 17942461 (4) (see all 32)
dutp	51.24	18	11920781 (1), 14761612 (1), 11867201 (1), 14739302 (1) (see all 15)
proline	51.05	271	14612423 (7), 11053443 (6), 8986812 (4), 16054204 (4) (see all 99)
o6-methylguanine	48.25	18	14724564 (2), 19107440 (1), 19047896 (1), 10945617 (1) (see all 13)

About this table

2 PharmGKB drug compound relationships for TP53 gene

Drug compound	PharmGKB Relations	PubMed IDs for articles supporting these relationships
mercaptopurine	CO PD PK FA GN	12704389 10406363
methotrexate	PD FA GN	12704389

About this table

(GenBank/EMBL/DDBJ Accessions according to
Unigene (Build 219 Homo sapiens; Jun 2 2009) or GenBank,
RefSeq according to Entrez Gene,
DOTS (version 10), and/or AceView,
non coding RNAs according to RNAdb,
ESTs according to GeneTide,
exon structure from GeneLoc, alternative splicing isoforms according to ASD and/or ECgene,
RNAi Products from Invitrogen, Millipore, and/or Abnova,
siRNAs from Applied Biosystems, Sigma-Aldrich,
shRNA from Sigma-Aldrich, OriGene,
Tagged/untagged cDNA clones from OriGene,
Expression Assays from Applied Biosystems)
About This Section

Inhib. RNA:		Invitrogen RNAi Products for gene knock-down (TP53)
		Millipore RNAi Products for the Analysis of TP53 Gene knock-down
		Abnova Chimera RNAi Products for Gene knock-down (TP53)

OriGene 29mer shRNA kit in GFP-retroviral vectors (see all 7): NM_001126112

Sigma-Aldrich siRNA for TP53

Sigma-Aldrich shRNA Panels and shRNA for TP53

Explore Sigma-Aldrich super-pooled esiRNAs

Applied Biosystems Silencer® siRNAs:

NM_000546 NM_001126112 NM_001126113 NM_001126114 NM_001126115 NM_001126116 NM_001126117

REFSEQ mRNAs for TP53 gene (7 alternative transcripts):

NM_000546.4 NM_001126112.1 NM_001126113.1 NM_001126114.1 NM_001126115.1 NM_001126116.1 NM_001126117.1

Applied Biosystems TaqMan ® Gene Expression Assays:

NM_000546 NM_001126112 NM_001126113 NM_001126114 NM_001126115 NM_001126116 NM_001126117

               OriGene GFP tagged cDNA clones in CMV expression vector (see all 7): NM_000546
                                 Myc/DDK tagged cDNA clones in CMV expression vector (see all 7): NM_000546
                                 untagged cDNA clones in CMV expression vector (see all 7): NM_000546

Additional cDNA sequence:

AB082923.1 AF052180.1 AF307851.1 AK223026.1 AK225838.1 AK297462.1 AK297927.1 AK303277.1

AK312568.1 AM076970.1 AM076971.1 AM076972.1 AY429684.1 AY627884.1 BC003596.1 BT019622.1

CR608294.1 CR624912.1 DQ186648.1 DQ186649.1 DQ186650.1 DQ186651.1 DQ186652.1 DQ191317.1

DQ263704.1 DQ286964.1 DQ401704.1 DQ485152.1 DQ648883.1 DQ648884.1 DQ648885.1 DQ648886.1

DQ648887.1 EF101867.1 EF101868.1 EF101869.1 FJ207420.1 M14694.1 M14695.1 S66666.1

X01405.1 X02469.1 X60010.1 X60011.1 X60012.1 X60013.1 X60014.1 X60015.1

X60016.1 X60017.1 X60018.1 X60019.1 X60020.1

18 DOTS entries:

DT.92469229 DT.100788714 DT.120961435 DT.100788713 DT.75152217 DT.40283865 DT.95274968 DT.100712946

DT.120961349 DT.100788719 DT.40120491 DT.120961395 DT.100788715 DT.92010563 DT.120961350 DT.120961391

DT.120961408 DT.99987012

24/112 AceView cDNA sequences (see all 112 ):

AW865736 X02469 AA379547 AA291539 AY627884 S66666 X60018 BE886147

AI539544 CK904490 CR608294 BU174921 AA358870 X60016 BQ057682 BQ066009

BX952582 CA432254 AA662570 BU673953 X60012 CR624912 BQ923115 AB082923

1 RNAdb entry of non coding RNAs:

LIT1750

highest scoring ESTs for TP53:

X02469 AA171861 AA296373 AB082923 AF307851 AU076984 AU120569 AU121050 AU129655 AU131952

Unigene Cluster for TP53:

Tumor protein p53

Hs.654481 [show with all ESTs]

Unigene Representative Sequence: NM_001126114

GeneLoc Exon Structure

5/9 Alternative Splicing Database (ASD) splice patterns (SP) for TP53 (see all 9 )

ExUns:	1a	·	1b	^	2	^	3	^	4	^	5a	·	5b	^	6	^	7	^	8	^	9a	·	9b	^	10a	·	10b	^	11	^	12a	·	12b	·	12c
SP1:											-										-				-		-
SP2:																					-
SP3:																					-				-
SP4:																					-				-		-
SP5:																									-		-

About this scheme

ECgene alternative splicing isoforms for TP53

3 Ensembl transcripts including schematic representations:

ENST00000396473 ENST00000359597 ENST00000269305

(Experimental results according to ¹GeneNote and GNF BioGPS,
probe sets-to-genes annotations according to ²GeneAnnot , ³GeneTide , Sets of similar genes according to GeneDecks, Electronic Northern calculations according to data from UniGene (Build 219 Homo sapiens), SAGE tags according to CGAP, plus additional links to SOURCE, and/or GNF BioGPS, and/or EXPOLDB, and/or UniProtKB,
Expression Assays from Applied Biosystems )
About This Section

TP53 expression in normal and diseased human tissues

Applied Biosystems TaqMan ® Gene Expression Assays for TP53

¹ / ² / ³

7 probe-sets matching TP53 gene

Affymetrix probe-set	Array	# genes	Sensitivity	Specificity	Correlation	Length	Gb_Accession	Consensus	Uniqueness	Score	Rank
Affymetrix probe-set	Array	GeneAnnot data			GeneNote data		GeneTide data
1974_s_at²^{, 3}	U95-A	1	1.00	1.00	0.82	0.88	X02469	1.00	1.00	1.00	1
1939_at²^{, 3}	U95-A	1	1.00	1.00	0.74	1.29	M22898	0.20	1.00	0.72	1
31618_at²^{, 3}	U95-A	1	1.00	1.00	0.54	0.84	S66666	0.60	1.00	0.82	1
211300_s_at²^{, 3}	U133-A	1	1.00	1.00	--	--	K03199	0.80	1.00	0.91	1
201746_at²^{, 3}	U133-A	1	1.00	1.00	--	--	NM_000546	0.60	1.00	0.82	1
211300_s_at²	U133Plus2	1	1.00	1.00	--	--	--	--	--	--	--
201746_at²	U133Plus2	1	1.00	1.00	--	--	--	--	--	--	--

GeneDecks TP53 for binary patterns associated with the probe-sets selected above

About GeneDecksing

About this table

Data from

(Publications) and GNF BioGPS
About these images
About these images

CGAP SAGE TAG: TTTTGTAGAG

SOURCE GeneReport for Unigene cluster: Hs.654481
Expression variation in blood from EXPOLDB for TP53

(Orthologs according to ^1,2HomoloGene (²older version, for species not in ¹newer version), ³euGenes, ⁴SGD and/or ⁵MGI Jun 06 2009, with possible further links to Flybase and/or WormBase, Gene Trees according to Ensembl)
About This Section

Orthologs for TP53 gene from 5/8 species (see all 8 )

Organism	Gene	Locus	Description	Human Similarity	NCBI accessions
dog (Canis familiaris)	TP53¹	--	tumor protein p53	84.3(n) 83.42(a)	403869 NM_001003210.1 NP_001003210.1
chimpanzee (Pan troglodytes)	TP53¹	--	tumor protein p53	99.75(n) 100(a)	455214 XM_001172091.1 XP_001172091.1
cow (Bos taurus)	TP53¹	--	tumor protein p53	83.9(n) 82.08(a)	281542 NM_174201.2 NP_776626.1
rat (Rattus norvegicus)	Tp53¹	--	tumor protein p53	81.44(n) 78.35(a)	24842 NM_030989.1 NP_112251.1
mouse (Mus musculus)	Trp53^{1, 5}	11 (39.00 cM)⁵	transformation related protein 53^{1, 5}	80.45(n)¹ 78.29(a)¹	22059¹ NM_011640.1¹ NP_035770.1¹ AB017815⁵ AB017816⁵ (see all 52)

About this table Species with no ortholog for TP53

ENSEMBL Gene Tree for TP53

(Paralogs according to ¹HomoloGene
and ²Ensembl, Pseudogenes according to ³Pseudogene.org)
About This Section

Paralogs for TP53 gene

TP73² TP63²

(According to the ¹NCBI SNP Database, ²Ensembl, ³PupaSUITE, and UniProtKB, Linkage Disequilibrium by HapMap, Genotyping Reagents from Applied Biosystems)
About This Section

10/340 NCBI SNPs in TP53 are shown (see all 340 )
(Click for Applied Biosystems TaqMan ® Genotyping Assay) (see all 120)

AB	SNP ID	Valid	Chr 17 pos	Sequence	Recs	AA Chg	Type	More	Recs	Pop	Total sample	More
AB	Genomic Data				Transcription Data				Allele Frequencies
				--	--	--		--	--			--
	rs1800371^1,2	C,F,H,O	7520273(-)	`TGTCCC/TCGGAC`	4	P/S	mis¹ ese³		13	MN NA NS EU EA WA	1326
	rs1042522^1,2	A,C,F,H	7520197(-)	`TCCCCG/CCGTGG`	4	R/P	mis¹		22	MN CSAM EA NS EU WA	2320
	rs2909430^1,2	A,C,F,H	7519370(-)	`CTTACA/GCATGT`	4	--	int¹ ut5¹		14	NS MN CSAM EA EU WA	1418
	rs9895829^1,2	C,F,H	7519404(+)	`GCTAGA/GGAGAG`	4	--	ut5¹ int¹		10	EU EA WA NS MN CSAM	974
	rs1614984^1,2	A,C,F	7512177(-)	`TAGGAC/TTGGGC`	1	--	ng5¹		6	NS MN CSAM EA	582
--	rs4968187^1,2	C,F,H	7513167(+)	`TAGACC/TCCATG`	7	--	ut3¹		16	NS EU EA WA MN CSAM	1660
	rs17883782^1,2	C,F	7512431(-)	`TGCAGG/CCTACT`	1	--	ng5¹		7	NS	842
--	rs17886358^1,2	C,F	7513083(-)	`AGCTGGT/-TAGGT`	7	--	ut3¹		6	NS MN CSAM EA	580
--	rs11540654^1,2	C,H	7520083(-)	`TTTCCC/G/TTCTGG`	8	R/P R/L	mis¹ ese³		9	MN CSAM EA EU WA	814
	rs17881366^1,2	C,F	7513324(-)	`TCACCG/ATACTA`	7	--	ut3¹ ese³		6	NS MN CSAM EA	588

About this table

HapMap Linkage Disequilibrium images for TP53 (up to first 250kb)

(in which this Gene is Involved, According to OMIM, UniProtKB, Novoseek, PharmGKB, Genatlas, GeneTests, Blood group antigen gene mutations by BGMUT, HGMD, GAD, HuGE Navigator, BCGD, and/or TGDB.)
About This Section

OMIM: 191170 disorders: 114500 151623 114550 259500 260500 161550 260350 202300 114480 151623

UniProtKB/Swiss-Prot: P53_HUMAN, P04637

TP53 is found in increased amounts in a wide variety of transformed cells. TP53 is

frequently mutated or inactivated in about 60% of cancers

Defects in TP53 are involved in esophageal squamous cell carcinoma (ESCC) [MIM:133239].

ESCC is a tumor of the esophagus

Defects in TP53 are a cause of Li-Fraumeni syndrome (LFS) [MIM:151623]. LFS is an

autosomal dominant familial cancer syndrome that in its classic form is defined by the existence

of a proband affected by a sarcoma before 45 years with a first degree relative affected by any

tumor before 45 years and another first degree relative with any tumor before 45 years or a

sarcoma at any age. Other clinical definitions for LFS have been proposed (PubMed:8118819 and

PubMed:8718514) and called Li-Fraumeni like syndrome (LFL). In these families affected relatives

develop a diverse set of malignancies at unusually early ages. Four types of cancers account for

80% of tumors occurring in TP53 germline mutation carriers: breast cancers, soft tissue and bone

sarcomas, brain tumors (astrocytomas) and adrenocortical carcinomas. Less frequent tumors include

choroid plexus carcinoma or papilloma before the age of 15, rhabdomyosarcoma before the age of 5,

leukemia, Wilms tumor, malignant phyllodes tumor, colorectal and gastric cancers

Defects in TP53 may be associated with nasopharyngeal carcinoma [MIM:161550]; also known

as nasopharyngeal cancer

Defects in TP53 are found in Barrett metaplasia; also known as Barrett esophagus. It is a

condition in which the normally stratified squamous epithelium of the lower esophagus is replaced

by a metaplastic columnar epithelium. The condition develops as a complication in approximately

10% of patients with chronic gastroesophageal reflux disease and predisposes to the development of

esophageal adenocarcinoma

Defects in TP53 are involved in head and neck squamous cell carcinomas (HNSCC)

[MIM:275355]

Defects in TP53 are involved in oral squamous cell carcinoma (OSCC). Cigarette smoke is a

prime mutagenic agent in cancer of the aerodigestive tract

Defects in TP53 are a cause of lung cancer [MIM:211980]

Defects in TP53 are a cause of choroid plexus papilloma [MIM:260500]. Choroid plexus

papilloma is a slow-growing benign tumor of the choroid plexus that often invades the

leptomeninges. In children it is usually in a lateral ventricle but in adults it is more often in

the fourth ventricle. Hydrocephalus is common, either from obstruction or from tumor secretion of

cerebrospinal fluid. If it undergoes malignant transformation it is called a choroid plexus

carcinoma. Primary choroid plexus tumors are rare and usually occur in early childhood

Defects in TP53 are a cause of one form of hereditary adrenocortical carcinoma (ADCC)

[MIM:202300]. ADCC is a rare childhood tumor, representing about 0.4% of childhood tumors, with a

high incidence of associated tumors. ADCC occurs with increased frequency in patients with the

Beckwith-Wiedemann syndrome [MIM:130650] and is a component tumor in Li-Fraumeni syndrome

[MIM:151623]

10/97 Novoseek disease relationships for TP53 gene (see all 97 )

Disease	Score	Articles	PubMed IDs for Articles with Shared Sentences (# sentences)
tumors	93.74	22625	8777377 (10), 7901994 (9), 8007011 (9), 8324748 (8) (see all 99)
li-fraumeni syndrome	90.46	320	1373881 (5), 17483435 (3), 10980596 (3), 10484981 (3) (see all 99)
cancer	89.81	6346	17598983 (10), 18223686 (8), 15055300 (7), 12561442 (7) (see all 99)
carcinoma	87.49	3225	9110348 (10), 8062281 (9), 16033093 (8), 7927312 (8) (see all 99)
carcinoma squamous cell	86.80	1827	9127380 (8), 8826924 (7), 10445528 (6), 11255264 (6) (see all 99)
retinoblastoma	85.08	679	10792093 (8), 9337350 (6), 11306502 (5), 8224613 (5) (see all 99)
microsatellite instability	84.49	335	9731891 (6), 9716224 (5), 11290569 (5), 12612901 (5) (see all 99)
allelic loss	83.88	399	16293976 (5), 7909153 (5), 8467510 (4), 11520271 (4) (see all 99)
adenocarcinoma	82.64	1486	12823203 (7), 17982662 (7), 9379505 (6), 10674608 (6) (see all 99)
breast cancer	81.53	2563	7917542 (8), 8679460 (8), 12170762 (7), 15566648 (6) (see all 99)

About this table

5 PharmGKB disease relationships for TP53 gene

Disease	PharmGKB Relations	PubMed IDs for articles supporting these relationships
Leukemia, Lymphocytic	CO PK GN	10406363
Leukemia, Lymphocytic, Acute, L1	PD FA GN	12704389
Neoplasms, Radiation-Induced	CO PK GN	10406363
Neoplasms, Second Primary	CO PK GN	10406363
Ovarian Neoplasms	CO GN	15221786

About this table

GeneTests: TP53

Li-Fraumeni Syndrome

Human Gene Mutation Database: TP53
Genetic Association Database: TP53
Human Genome Epidemiology Navigator: TP53 (724 documents)
Tumor Gene Database: TP53
Breast Cancer Gene Database: TP53

(Possibly Related Articles in Doctor's Guide)
About This Section

(in PubMed. Associations of this gene to articles via ¹Novoseek, ²HGNC, ³Entrez Gene, ⁴UniProtKB/Swiss-Prot, ⁵UniProtKB/TrEMBL, ⁶GAD, and/or ⁷PharmGKB)
About This Section

100/11043 PubMed articles for TP53 gene (see all 11043 ):

Isolation and characterization of a human p53 cDNA clone: expression of the human p53 gene. (PubMed id 6396087)^{2, 3, 4} Matlashewski G....Benchimol S. (1984)
Hereditary TP53 codon 292 and somatic P16INK4A codon 94 mutations in a Li-Fraumeni syndrome family. (PubMed id 10484981)^{1, 3, 4} Gueran S.... Imirzalioglu N. (1999)
Spectrum of p53 tumor suppressor gene mutations and breast cancer survival. (PubMed id 14997055)^{1, 3, 6} Lai H....Lai S. (2004)
Structure of the MDM2 oncoprotein bound to the p53 tumor suppressor transactivation domain. (PubMed id 8875929)^{1, 3, 4} Kussie P.H.... Pavletich N.P. (1996)
Joint effects of single nucleotide polymorphisms in P53BP1 and p53 on breast cancer risk in a Chinese population. (PubMed id 16314399)^{1, 3, 6} Ma H....Shen H. (2006)
p53 codon 72 and MDM2 SNP309 polymorphisms and age of colorectal cancer onset in Lynch syndrome. (PubMed id 16203772)^{1, 3, 6} Sotamaa K....de la Chapelle A. (2005)
Lung cancer risk in germline p53 mutation carriers: association between an inherited cancer predisposition, cigarette smoking, and cancer risk. (PubMed id 12802680)^{1, 3, 6} Hwang S.J....Strong L.C. (2003)
[p53 gene polymorphism with susceptibility to esophageal cancer and lung cancer in Chinese population] (PubMed id 12921568)^{1, 3, 6} Zhang J.H....He M. (2003)
Genetic polymorphisms in cell cycle regulatory genes MDM2 and TP53 are associated with susceptibility to lung cancer. (PubMed id 16287156)^{1, 3, 6} Zhang X....Lin D. (2006)
Association of genetic polymorphisms of MK, IL-4, p16, p21, p53 genes and human gastric cancer in Taiwan. (PubMed id 16289646)^{1, 3, 6} Lai K.C....Tsai F.J. (2005)
Determination of TP53 mutation is more relevant than microsatellite instability status for the prediction of disease-free survival in adjuvant-treated stage III colon cancer patients. (PubMed id 16110022)^{1, 3, 6} Westra J.L....Plukker J.T. (2005)
Molecular analysis of the TP53 gene in Barrett's adenocarcinoma. (PubMed id 8829627)^{1, 3, 4} Audrezet M.-P.... Ferec C. (1996)
TP53 mutations in breast cancer tumors of patients from Rio de Janeiro, Brazil: association with risk factors and tumor characteristics. (PubMed id 12209590)^{1, 3, 6} Simao T.A....de Moura-Gallo C.V. (2002)
FGFR3 and Tp53 mutations in T1G3 transitional bladder carcinomas: independent distribution and lack of association with prognosis. (PubMed id 16061860)^{1, 3, 6} Hernandez S....Real F.X. (2005)
Human TP53 from the malignant glioma-derived cell lines M059J and M059K has a cancer-associated mutation in exon 8. (PubMed id 11023613)^{1, 3, 4} Anderson C.W. and Allalunis-Turner M.J. (2000)
Characterization of a frequent polymorphism in the coding sequence of the Tp53 gene in colonic cancer patients and a control population. (PubMed id 1999338)^{1, 3, 4} Olschwang S.... Thomas G. (1991)
TP53 and P21 polymorphisms: response to cisplatinum/paclitaxel-based chemotherapy in ovarian cancer. (PubMed id 16364249)^{3, 6} Santos A.M....Medeiros R. (2006)
Age of diagnosis of colorectal cancer in HNPCC patients is more complex than that predicted by R72P polymorphism in TP53. (PubMed id 16353134)^{3, 6} Talseth B.A....Scott R.J. (2006)
Association between TP53 and p21 genetic polymorphisms and acute side effects of radiotherapy in breast cancer patients. (PubMed id 16331344)^{3, 6} Tan X.L....Chang-Claude J. (2006)
Genetic variants of TP53 and EPHX1 in Leber's hereditary optic neuropathy and their relationship to age at onset. (PubMed id 15838728)^{3, 6} Ishikawa K....Mashima Y. (2005)
Association of amino acid substitution polymorphisms in DNA repair genes TP53, POLI, REV1 and LIG4 with lung cancer risk. (PubMed id 15609317)^{3, 6} Sakiyama T....Yokota J. (2005)
TP53-binding protein variants and breast cancer risk: a case-control study. (PubMed id 15987456)^{3, 6} Frank B....Burwinkel B. (2005)
TP53 and KRAS mutation load and types in lung cancers in relation to tobacco smoke: distinct patterns in never, former, and current smokers. (PubMed id 15958551)^{3, 6} Le Calvez F....Hainaut P. (2005)
Effect of the codon 72 polymorphism (c.215G>C, p.Arg72Pro) in combination with somatic sequence variants in the TP53 gene on survival in patients with advanced ovarian carcinoma. (PubMed id 15221786)^{1, 7} Wang Y....Helland A. (2004)
TP53 haplotype-based analysis and incidence of post-angioplasty restenosis. (PubMed id 14740296)^{3, 6} Zee R.Y....Lindpaintner K. (2004)
A TP53 polymorphism is associated with increased risk of colorectal cancer and with reduced levels of TP53 mRNA. (PubMed id 14647431)^{3, 6} Gemignani F....Canzian F. (2004)
TP53INP1s and homeodomain-interacting protein kinase-2 (HIPK2) are partners in regulating p53 activity. (PubMed id 12851404)^{3, 4} Tomasini R.... Dusetti N.J. (2003)
Different risk relations with smoking for non-small-cell lung cancer: comparison of TP53 and TP73 genotypes. (PubMed id 12875622)^{3, 6} Hiraki A....Tajima K. (2003)
Relationships of TP53 codon 72 and HRAS1 polymorphisms with lung cancer risk in an ethnically diverse population. (PubMed id 11097227)^{3, 6} Pierce L.M....Le Marchand L. (2000)
An extended Li-Fraumeni kindred with gastric carcinoma and a codon 175 mutation in TP53. (PubMed id 8825920)^{3, 4} Varley J.M....Evans D.G.R. (1995)
Gene expression profiling of isogenic cells with different TP53 gene dosage reveals numerous genes that are affected by TP53 dosage and identifies CSPG2 as a direct target of p53. (PubMed id 12438652)^{1, 3} Yoon H....Pellegata N.S. (2002)
Prognostic significance of ATM and TP53 deletions in Chinese patients with chronic lymphocytic leukemia. (PubMed id 18035414)^{1, 3} Xu W....Qiu H.X. (2008)
RB1 and TP53 pathways in radiation-induced sarcomas. (PubMed id 17369843)^{1, 3} Gonin-Laurent N....Malfoy B. (2007)
Polymorphisms in TP53 and MDM2 combined are associated with high grade endometrial cancer. (PubMed id 19193430)^{1, 3} Ashton K.A....Scott R.J. (2009)
Association study of TP53 polymorphisms with lung cancer in a Korean population. (PubMed id 18363031)^{1, 3} Jung H.Y....Kim Y.H. (2008)
Common Polymorphisms in the MDM2 and TP53 Genes and the Relationship between TP53 Mutations and Patient Outcomes in Glioblastomas. (PubMed id 18462472)^{1, 3} Zawlik I....Ohgaki H. (2008)
Assessment of TP53 mutation using purified tissue samples of ovarian serous carcinomas reveals a higher mutation rate than previously reported and does not correlate with drug resistance. (PubMed id 17692090)^{1, 3} Salani R....Shih I.M. (2008)
Mutations in TP53 are a prognostic factor in colorectal hepatic metastases undergoing surgical resection. (PubMed id 17259658)^{1, 3} Mollevi D.G....Villanueva A. (2007)
Breast-cancer stromal cells with TP53 mutations and nodal metastases. (PubMed id 18094375)^{1, 3} Patocs A....Eng C. (2007)
Somatic TP53 mutations are relatively rare among adrenocortical cancers with the frequent 17p13 loss of heterozygosity. (PubMed id 17289876)^{1, 3} Libe R....Bertherat J. (2007)
TP53 mutational pattern in Spanish and Polish non-small cell lung cancer patients: null mutations are associated with poor prognosis. (PubMed id 9416838)^{1, 6} de Anta J.M....Sanchez-Cespedes M. (1997)
Mutational inactivation of the nijmegen breakage syndrome gene (NBS1) in glioblastomas is associated with multiple TP53 mutations. (PubMed id 19151620)^{1, 3} Watanabe T....Ohgaki H. (2009)
Tissue array for Tp53, C-myc, CCND1 gene over-expression in different tumors. (PubMed id 19084934)^{1, 3} Liu G.Y....Gao H.Z. (2008)
Type of TP53 mutation and ERBB2 amplification affects survival in node-negative breast cancer. (PubMed id 17221157)^{1, 3} Ozcelik H....Andrulis I.L. (2007)
TP53 mutations in human cancers: functional selection and impact on cancer prognosis and outcomes. (PubMed id 17401424)^{1, 3} Petitjean A....Olivier M. (2007)
Genetic polymorphisms in TP53, nonsteroidal anti-inflammatory drugs and the risk of colorectal cancer: evidence for gene-environment interaction? (PubMed id 17622940)^{1, 3} Tan X.L....Chang-Claude J. (2007)
TP53 gene mutations are rare in nondysplastic Barrett's esophagus. (PubMed id 16416221)^{1, 3} Novotna K....Sedlacek Z. (2006)
BRCA1, BRCA2 and TP53 mutations in very early-onset breast cancer with associated risks to relatives. (PubMed id 16644204)^{1, 3} Lalloo F....Evans D.G. (2006)
TP53 alterations and patterns of carcinogen exposure in a U.S. population-based study of bladder cancer. (PubMed id 15906354)^{1, 3} Kelsey K.T....Karagas M. (2005)
Worse survival for TP53 (p53)-mutated breast cancer patients receiving adjuvant CMF. (PubMed id 15802278)^{1, 3} Andersson J....Bergh J. (2005)
Human papillomavirus type 16 and TP53 mutation in oral cancer: matched analysis of the IARC multicenter study. (PubMed id 14744758)^{1, 3} Dai M....Franceschi S. (2004)
TP53 codon 72 polymorphism does not affect risk of cervical cancer in patients from The Gambia. (PubMed id 14756543)^{1, 3} Tanara G....Cosimi A. (2003)
TP53 gene mutations predict the response to neoadjuvant treatment with 5-fluorouracil and mitomycin in locally advanced breast cancer. (PubMed id 14654539)^{1, 3} Geisler S....Lonning P.E. (2003)
Tissue polypeptide antigen (TPA) in comparison with mutations of tumour suppressor gene P53 (TP53) in patients with bladder cancer. (PubMed id 12820330)^{1, 3} Ecke T.H....Loening S.A. (2003)
Selection pressures of TP53 mutation and microenvironmental location influence epidermal growth factor receptor gene amplification in human glioblastomas. (PubMed id 12543796)^{1, 3} Okada Y....Louis D.N. (2003)
TP53 mutations predict disease control in metastatic colorectal cancer treated with cetuximab-based chemotherapy. (PubMed id 19367287)^{1, 3} Oden-Gangloff A....Frebourg T. (2009)
Prognostic implication of EGFR, KRAS, and TP53 gene mutations in a large cohort of Japanese patients with surgically treated lung adenocarcinoma. (PubMed id 19096302)^{1, 3} Kosaka T....Mitsudomi T. (2009)
Chromosomal imbalances, loss of heterozygosity, and immunohistochemical expression of TP53, RB1, and PTEN in intraductal cancer, intraepithelial neoplasia, and invasive adenocarcinoma of the prostate. (PubMed id 18383208)^{1, 3} Bettendorf O....Semjonow A. (2008)
Relationship of Ki67, TP53, MDM-2 and BCL-2 expressions with WHO 1973 and WHO/ISUP grades, tumor category and overall patient survival in urothelial tumors of the bladder. (PubMed id 18572327)^{1, 3} Gonul I.I....Kupeli B. (2008)
Detection of R337H, a germline TP53 mutation predisposing to multiple cancers, in asymptomatic women participating in a breast cancer screening program in Southern Brazil. (PubMed id 18248785)^{1, 3} Palmero E.I....Ashton-Prolla P. (2008)
Human germline and somatic cells have similar TP53 and Kirsten-RAS gene single base mutation frequencies. (PubMed id 18418864)^{1, 3} Cole D.N....Wilson V.L. (2008)
TP53 gene mutations of lung cancer patients in upper northern Thailand and environmental risk factors. (PubMed id 18656689)^{1, 3} Bumroongkit K....Kangwanpong D. (2008)
A comparison between p53 accumulation determined by immunohistochemistry and TP53 mutations as prognostic variables in tumours from breast cancer patients. (PubMed id 18465328)^{1, 3} Alsner J....Overgaard J. (2008)
NSAIDs modulate CDKN2A, TP53, and DNA content risk for progression to esophageal adenocarcinoma. (PubMed id 17326708)^{1, 3} Galipeau P.C....Reid B.J. (2007)
TP53 mutation status and gene expression profiles are powerful prognostic markers of breast cancer. (PubMed id 17504517)^{1, 3} Langerod A....Jeffrey S.S. (2007)
Patterns of EGFR, HER2, TP53, and KRAS mutations of p14arf expression in non-small cell lung cancers in relation to smoking history. (PubMed id 17575133)^{1, 3} Mounawar M....Hainaut P. (2007)
A novel nuclear factor-kappaB gene signature is differentially expressed in head and neck squamous cell carcinomas in association with TP53 status. (PubMed id 17908957)^{1, 3} Lee T.L....Chen Z. (2007)
Single-nucleotide polymorphisms at the TP53-binding or responsive promoter regions of BAX and BCL2 genes and risk of squamous cell carcinoma of the head and neck. (PubMed id 17693666)^{1, 3} Chen K....Wei Q. (2007)
Telomere length in peripheral blood cells of germline TP53 mutation carriers is shorter than that of normal individuals of corresponding age. (PubMed id 17567834)^{1, 3} Trkova M....Sedlacek Z. (2007)
Molecular detection of TP53, Ki-Ras and p16INK4A promoter methylation in plasma of patients with colorectal cancer and its association with prognosis. Results of a 3-year GOIM (Gruppo Oncologico dell'Italia Meridionale) prospective study. (PubMed id 16760301)^{1, 3} Bazan V....Russo A. (2006)
TP53 and KRAS2 mutations in plasma DNA of healthy subjects and subsequent cancer occurrence: a prospective study. (PubMed id 16818665)^{1, 3} Gormally E....Hainaut P. (2006)
Increased risk of non-small cell lung cancer and frequency of somatic TP53 gene mutations in Pro72 carriers of TP53 Arg72Pro polymorphism. (PubMed id 16499995)^{1, 3} Szymanowska A....Jassem J. (2006)
TP53 mutation, allelism and survival in non-small cell lung cancer. (PubMed id 15905205)^{1, 3} Nelson H.H....Kelsey K.T. (2005)
Prognostic significance of TP53 tumor suppressor gene expression and mutations in human osteosarcoma: a meta-analysis. (PubMed id 15448009)^{1, 3} Pakos E.E....Ioannidis J.P. (2004)
Absence of association between HPV DNA, TP53 codon 72 polymorphism, and risk of oesophageal cancer in a high-risk area of China. (PubMed id 11146230)^{1, 3} Peixoto Guimaraes D....Hainaut P. (2001)
TP53 codon 72 polymorphism is associated with age at onset of glioblastoma. (PubMed id 19171829)^{1, 3} El Hallani S....Sanson M. (2009)
Haplotype analysis of TP53 polymorphisms, Arg72Pro and Ins16, in BRCA1 and BRCA2 mutation carriers of French Canadian descent. (PubMed id 18402691)^{1, 3} Cavallone L....Tonin P.N. (2008)
KLF6 and TP53 mutations are a rare event in prostate cancer: distinguishing between Taq polymerase artifacts and true mutations. (PubMed id 19020536)^{1, 3} Agell L....Lloreta J. (2008)
TP53 gene mutations as an independent marker for urinary bladder cancer progression. (PubMed id 18425359)^{1, 3} Ecke T.H....Schlechte H.H. (2008)
Germline TP53 mutations in BRCA1 and BRCA2 mutation-negative French Canadian breast cancer families. (PubMed id 17541742)^{1, 3} Arcand S.L....Tonin P.N. (2008)
[Association of TP53 gene polymorphisms with genetic susceptibility to liver metastases of colorectal cancer] (PubMed id 18393238)^{1, 3} Wang A.Z....Cong W.M. (2008)
An increased lung cancer risk associated with codon 72 polymorphism in the TP53 gene and human papillomavirus infection in Mazandaran province, Iran. (PubMed id 17208332)^{1, 3} Nadji S.A....Mokhtari-Azad T. (2007)
Common variants in the ATM, BRCA1, BRCA2, CHEK2 and TP53 cancer susceptibility genes are unlikely to increase breast cancer risk. (PubMed id 17428325)^{1, 3} Baynes C....Dunning A.M. (2007)
BRCA1 and TP53 mutation spectrum of breast carcinoma in an ethnic population of Kashmir, an emerging high-risk area. (PubMed id 16996204)^{1, 3} Eachkoti R....Siddiqi M.A. (2007)
Polymorphisms in insulin-related genes predispose to specific KRAS2 and TP53 mutations in colon cancer. (PubMed id 16448675)^{1, 3} Samowitz W.S....Slattery M.L. (2006)
Unique substitution of CHEK2 and TP53 mutations implicated in primary prostate tumors and cancer cell lines. (PubMed id 16941491)^{1, 3} Zheng L....Liu W. (2006)
Mutations in exons 6 and 7 of TP53 gene correlate positively with serum tumor necrosis factor alpha independent of microsatellite instability in BAT26 gene in Egyptian patients with endometrial carcinoma. (PubMed id 17013801)^{1, 3} Diab A.M....Elsammak M. (2006)
The possible role of TP53 mutation status in the treatment of squamous cell carcinomas of the head and neck (HNSCC) with radiotherapy with different overall treatment times. (PubMed id 16024113)^{1, 3} Eriksen J.G....Overgaard J. (2005)
Mutation analysis of genes that control the G1/S cell cycle in melanoma: TP53, CDKN1A, CDKN2A, and CDKN2B. (PubMed id 15819981)^{1, 3} Soto J.L....Lopez-Nevot M.A. (2005)
Microarray analysis reveals that TP53- and ATM-mutant B-CLLs share a defect in activating proapoptotic responses after DNA damage but are distinguished by major differences in activating prosurvival responses. (PubMed id 12958068)^{1, 3} Stankovic T....Taylor A.M. (2004)
The TP53 tumor suppressor gene and melanoma tumorigenesis: is there a relationship? (PubMed id 15557758)^{1, 3} Hussein M.R. (2004)
TP53, BRCA1, and BRCA2 tumor suppressor genes are not commonly mutated in survivors of Hodgkin's disease with second primary neoplasms. (PubMed id 14673037)^{1, 3} Nichols K.E....Diller L. (2003)
Discordance of genetic alterations between primary head and neck tumors and corresponding metastases associated with mutational status of the TP53 gene. (PubMed id 11793443)^{1, 3} Tabor M.P....Brakenhoff R.H. (2002)
Analysis of BRCA1, TP53, and TSG101 germline mutations in German breast and/or ovarian cancer families. (PubMed id 12505256)^{1, 3} Balz V....Bojar H. (2002)
Frequent somatic mutations in PTEN and TP53 are mutually exclusive in the stroma of breast carcinomas. (PubMed id 12379854)^{1, 3} Kurose K....Eng C. (2002)
Association of p53 accumulation with TP53 mutations, loss of heterozygosity at 17p13, and DNA ploidy status in 273 colorectal carcinomas. (PubMed id 9917132)^{1, 6} Clausen O.P....Meling G.I. (1998)
Polymorphisms and DNA methylation of gene TP53 associated with extra-axial brain tumors. (PubMed id 19224462)^{1, 3} Almeida L.O....Casartelli C. (2009)
TP53 mutations predict for poor survival in de novo diffuse large B-cell lymphoma of germinal center subtype. (PubMed id 18706692)^{1, 3} Zainuddin N....Enblad G. (2009)
Mutational analysis of KRAS, BRAF, and TP53 genes of ovarian serous carcinomas in Korean women. (PubMed id 19430562)^{1, 3} Cho Y.H....Kim Y.T. (2009)
Common genetic variation in TP53 and risk of human papillomavirus persistence and progression to CIN3/cancer revisited. (PubMed id 19423538)^{1, 3} Koshiol J....Wang S.S. (2009)

(in PubMed, OMIM, and NCBI Bookshelf)
About This Section

		AND	OR
Aliases
Disorders
Search String
Free Text

Query String		PubMed OMIM NCBI Bookshelf
	(Note: In FireFox, select the above section and copy using Ctrl-C)

(According to Entrez Gene, HGNC, AceView, euGenes, Ensembl, miRBase, ECgene, and/or H-InvDB)
About This Section

Entrez Gene: 7157	HGNC: 11998	AceView: TP53	Ensembl:ENSG00000141510	euGenes: HUgn7157
ECgene: TP53	H-InvDB: TP53

(According to HUGE)
About This Section

(According to ATLAS, HORDE, IMGT, MTDB, LEIDEN, UniProtKB/Swiss-Prot, and/or UniProtKB/TrEMBL,
Wikipedia and/or GeneReviews via UniProtKB/Swiss-Prot)
About This Section

Name	Description
ATLAS Chromosomes in Cancer entry for TP53	Genetics and Cytogenetics in Oncology and Haematology
IARC TP53 mutation database	http://www-p53.iarc.fr/
p53 web site at the Institut Curie	http://p53.free.fr/
GeneReviews	http://www.genetests.org/query?gene=TP53
NIEHS-SNPs	http://egp.gs.washington.edu/data/tp53/
SHMPD	http://shmpd.bii.a-star.edu.sg/gene.php?genestart=A&genename=TP53
Wikipedia	http://en.wikipedia.org/wiki/P53

Licensable Technologies for TP53
(Available from WIS Yeda, Salk, Tufts)

About This Section

Licensable Technologies for TP53 gene:

	Weizmann Institute:	Treatment of Systemic Lupus Erythematosus by Down-Regulating the Autoimmune Response to Autoantigens	(see all 2)
	Salk Institute:	Assays for p53 Function in Cells

(Reagents available from Applied Biosystems, Antibodies and assays by Cell Signaling Technology, Abcam, Novus Biologicals,
Sigma-Aldrich, R&D Systems, Millipore, Abnova, and/or Invitrogen, Clones available from OriGene,and/or Invitrogen, Drugs and/or compounds by Sigma-Aldrich,
Enzo Life Sciences, and/or Tocris Bioscience)
About This Section

Products for TP53:

TaqMan ® Gene Expression Assays

TaqMan ® Genotyping Assays

Free SNP selection tool

Invitrogen iPath Pathways	Invitrogen BLOCK-iT™ RNAi
Invitrogen Antibodies	Invitrogen Assays
Invitrogen Clones	Invitrogen Q-PCR Products
Invitrogen Human Recombinant Kinases	Invitrogen Custom Antibody and Peptide Service
Invitrogen Proteins / Assays / Screening Services	Search Invitrogen catalog for TP53-related products

	Millipore Custom Antibody & Bulk Services
	Millipore Preclinical / Clinical Development Services
	Millipore Immunoassay Services
	Millipore Target Screening & Profiling Services

	Predesigned and custom siRNAs for TP53		Antibodies for TP53
	Explore super-pooled esiRNAs		Proteins for TP53
	Lentivirus-delivered shRNAs for TP53		Browse small molecules at Sigma-Aldrich
	"Your Favorite Gene" Pathways		feedback

	Antibodies		Primer Pairs
	Cell Culture Products		ELISAs
	Flow Cytometry Kits		Protease Activity Assays & Reagents
	Cell Selection/Detection Kits & Reagents		ELISA/Assay Development Kits & Reagents
	Multiplex/Array Assay Kits & Reagents		ELISpot Kits & Development Modules
	Recombinant & Natural Proteins

	Recombinant Proteins (TP53)
	Antibodies (TP53)
	Chimera RNAi (TP53)
	Custom Service for Mouse Mab
	Custom Service for Rabbit Pab from Full-length Protein

Antibodies & Assays for TP53 (p53)

	Recombinant Proteins (p53 gamma, p53, p53 beta, Mutant p53)
	Antibodies (p53 gamma, p53, p53 beta, Mutant p53)

	Tagged/untagged cDNA clones
	Validated SYBR primer pairs
	Purified proteins from HEK293T cells
	Western blot validated antibodies
	shRNA in GFP-retroviral vector

Tocris compounds for TP53

	Proteins for TP53
	Search www.enzolifesicences.com for proteins, assays, substrates, inhibitors & antibodies

Antibodies for TP53

GeneCards Homepage - Last full update: 2 Jul 2009 Incremental update: 13 Oct 2009

Random Gene From GIFtS :

about GIFtS

Gene Index: 3 5 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

Developed at the Crown Human Genome Center & Weizmann Institute of Science

The GeneCards Human Gene Database: Copyright © 1996-2009, Weizmann Institute of Science. All Rights Reserved.
TP53 Gene at Home site.
Version 2.41.1
server5.xennexinc.com

TP53 Gene

protein-coding GIFtS: 82

Aliases &
Descriptions
for TP53

Summaries
for TP53

Genomic Location
for TP53

Proteins
for TP53

Protein Domains/
Families
for TP53

Gene Function
for TP53

Pathways & Interactions
for TP53

Drugs & Compounds
for TP53

Transcripts
for TP53

Expression
for TP53

Orthologs
for TP53

Paralogs
for TP53

SNPs/Variants
for TP53

Disorders & Mutations
for TP53

Medical News
for TP53

Publications
for TP53

Search for TP53

Genome Databases showing TP53

Other Databases showing TP53

Specialized Databases showing TP53

Licensable Technologies
for TP53

Services
for TP53

Gene Index: 3 5 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

TP53 Gene

protein-coding GIFtS: 82

Aliases & Descriptionsfor TP53

Summariesfor TP53

Genomic Locationfor TP53

Proteinsfor TP53

Protein Domains/Familiesfor TP53

Gene Functionfor TP53

Pathways & Interactionsfor TP53

Drugs & Compoundsfor TP53

Transcriptsfor TP53

Expression for TP53

Orthologsfor TP53

Paralogsfor TP53

SNPs/Variantsfor TP53

Disorders & Mutationsfor TP53

Medical Newsfor TP53

Publicationsfor TP53

Search for TP53

Genome Databases showing TP53

Other Databases showing TP53

Specialized Databases showing TP53

Licensable Technologiesfor TP53

Servicesfor TP53

Gene Index: 3 5 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

Aliases &
Descriptions
for TP53

Summaries
for TP53

Genomic Location
for TP53

Proteins
for TP53

Protein Domains/
Families
for TP53

Gene Function
for TP53

Pathways & Interactions
for TP53

Drugs & Compounds
for TP53

Transcripts
for TP53

Expression
for TP53

Orthologs
for TP53

Paralogs
for TP53

SNPs/Variants
for TP53

Disorders & Mutations
for TP53

Medical News
for TP53

Publications
for TP53

Licensable Technologies
for TP53

Services
for TP53